- have liver problems
- plan to have surgery
- have chicken pox or measles or have recently been near anyone with chicken pox or measles
- have an infection
- have high blood sugar levels (prediabetes or diabetes)
- have glaucoma or cataracts
- have a family history of diabetes or glaucoma
- have or have had tuberculosis
- have high blood pressure (hypertension)
DISCOVER TARPEYO
The first FDA-approved treatment to reduce proteinuria in adults with IgA Nephropathy (IgAN) at risk of rapid disease progression

Specifically designed for and studied in IgAN
TARPEYO is the first FDA-approved therapy that was specifically designed for IgAN

Targets a source of IgAN in the gut
Designed to deliver treatment to an area of the gut thought to play a role in IgAN*

Significantly reduced protein in urine
34% reduction seen in the TARPEYO-treated group vs 5% reduction in the placebo plus blood pressure medication group†

Once-daily oral medicine
4 capsules of TARPEYO should be taken once a day and swallowed whole
Please see information for how to take TARPEYO and what to avoid while taking TARPEYO here
.*It has not been established to what extent the efficacy of TARPEYO is from local effects (in the gut) vs systemic effects (in circulation).
†In Part A of the TARPEYO clinical study, 97 patients received TARPEYO plus blood pressure medication, and 102 patients received placebo plus blood pressure medication.
HOW IS TARPEYO THOUGHT TO WORK?


TARPEYO is designed to deliver treatment to an area of the gut thought to play a role in IgAN.
Types of cells in the gut are responsible for the production of an antibody called IgA1, which can build up in the kidneys, causing IgAN. TARPEYO can reduce the amount of this antibody.‡
‡It has not been established to what extent the efficacy of TARPEYO is from local effects (in the gut) vs systemic effects (in circulation).
WHAT IS UNIQUE ABOUT TARPEYO?
The TARPEYO capsule was designed with targeted-release technology to dissolve once it reaches a specific area of the gut thought to play a role in IgAN

HOW WAS TARPEYO STUDIED?
TARPEYO was specifically studied in a large trial of patients with IgAN
Part A of the clinical study of TARPEYO was the pivotal placebo-controlled efficacy and safety trial that served as the basis for the FDA accelerated approval
97
patients received TARPEYO plus blood pressure medication
102
patients received placebo plus blood pressure medication
- Primary objective: See how TARPEYO reduced high levels of protein in the urine (proteinuria) after 9 months of treatment, as measured by urine protein-to-creatinine ratio (UPCR)
- Estimated glomerular filtration rate (eGFR) was a selected secondary objective in this part of the study
- Part B of the clinical study is a follow-up study for full approval that will assess eGFR over 2 years for patients who were treated with TARPEYO or placebo in Part A
TARPEYO STUDY RESULTS
Proven to lower urine protein levels at 9 months (primary objective of study)§


§At 9 months, 97 patients received treatment with TARPEYO plus blood pressure medication and 102 patients received placebo plus blood pressure medication.
Change in eGFR at 9 months (secondary objective of the study)


As kidney function worsens, the eGFR number goes down.
It has not yet been established whether TARPEYO has demonstrated a benefit in slowing kidney function decline in patients with IgAN.
||At the start of study, the average eGFR was 54.9 mL/min/1.73 m2 in the TARPEYO group and 55.5 mL/min/1.73 m2 in the placebo group.
The overall impact on slowing kidney function decline as measured by eGFR is the focus of Part B of the study.
TARPEYO SAFETY PROFILE
TARPEYO may cause serious side effects, including:
TARPEYO may cause serious side effects, including:
- Effects of having too much corticosteroid medicine in your blood (hypercorticism), adrenal suppression, and risk of immunosuppression
- Please see detailed Important Safety Information
THE MOST COMMON SIDE EFFECTS REPORTED BY PATIENTS IN THE CLINICAL STUDY OF TARPEYO


TARPEYO may cause serious side effects, including effects of having too much corticosteroid medicine in your blood (hypercorticism), adrenal suppression, and risk of immunosuppression.
Approximately 90% of patients in the clinical study stayed on TARPEYO during the 9-month treatment period

Blood pressure: Increases in blood pressure were small and resolved to baseline levels by the end of the 9-month treatment period

Weight gain: Increases in body weight were minor and did not exceed 2.2 lbs. Patients returned to pre-treatment weight within 3 months of ending treatment
Unlike with other products, there are no FDA-mandated tests for TARPEYO; however, your doctor will likely order lab tests to determine how well you are responding to treatment.
The TARPEYO Patient Brochure provides helpful information about TARPEYO.